Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 2/2013

01.06.2013

Durable complete remission after brentuximab vedotin in a patient with relapsed and refractory Hodgkin lymphoma (HL)

verfasst von: Prof. Dr. Johannes Drach, MD, Ihor Huk, Wolfgang Lamm

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

We present a case of a 23-year-old female patient with relapsed classical Hodgkin lymphoma in reduced general condition. She was refractory after multiple lines of prior chemotherapy including autologous stem cell transplantation. By applying a targeted therapy concept using brentuximab vedotin (SGN-35), the patient experienced a rapid clinical improvement with loss of B symptoms immediately after the first treatment cycle. Elevated serum levels for C-reactive protein (CRP) and lactate dehydrogenase (LDH) returned to normal, and a significant improvement of hemoglobin levels were observed. Moreover, after administration of 16 cycles, the patient remains in complete remission, lasting now for > 15 months. Tolerability of treatment was excellent without evidence of infections or peripheral neuropathy. This case illustrates the clinical potential of brentuximab vedotin in patients with end-stage Hodgkin lymphoma who would otherwise have only limited treatment options.
Literatur
1.
Zurück zum Zitat Jona A, Younes A. Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma. Blood Rev. 2010;24:233–8.PubMedCrossRef Jona A, Younes A. Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma. Blood Rev. 2010;24:233–8.PubMedCrossRef
2.
Zurück zum Zitat Hoppe RT, Advani RH, Ai WZ, et al. Hodgkin lymphoma, version 2.2012 featured updates of the NCCN guidelines. J Natl Compr Cancer Net. 2012;10(5):589–97. Hoppe RT, Advani RH, Ai WZ, et al. Hodgkin lymphoma, version 2.2012 featured updates of the NCCN guidelines. J Natl Compr Cancer Net. 2012;10(5):589–97.
3.
Zurück zum Zitat Eichenauer DA, Engert A, Dreyling M. Hodgkin’s lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22(Suppl 6):vi55–8. Eichenauer DA, Engert A, Dreyling M. Hodgkin’s lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22(Suppl 6):vi55–8.
4.
Zurück zum Zitat Horning SJ, Fanale M, de Vos S, et al. Defining a population of Hodgkin lymphoma patients for novel therapeutics: an international effort. Ann Oncol. 2008;20:Abstract 118. Horning SJ, Fanale M, de Vos S, et al. Defining a population of Hodgkin lymphoma patients for novel therapeutics: an international effort. Ann Oncol. 2008;20:Abstract 118.
5.
Zurück zum Zitat Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812–21.PubMedCrossRef Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812–21.PubMedCrossRef
6.
Zurück zum Zitat Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30:1–7.CrossRef Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30:1–7.CrossRef
7.
Zurück zum Zitat Smith SE, Chen R, Gopal AK, et al. Long-term follow-up results of an ongoing pivotal study of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma (HL). EHA, Abstract #1109, June 14–17 2012, Amsterdam. Smith SE, Chen R, Gopal AK, et al. Long-term follow-up results of an ongoing pivotal study of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma (HL). EHA, Abstract #1109, June 14–17 2012, Amsterdam.
8.
Zurück zum Zitat Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol. 2012;30(7):631–7.PubMedCrossRef Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol. 2012;30(7):631–7.PubMedCrossRef
9.
Zurück zum Zitat Katz J, Janik JE, Younes A. Brentuximab vedotin (SGN-35). Clin Cancer Res. 2011;17:6428–36.PubMedCrossRef Katz J, Janik JE, Younes A. Brentuximab vedotin (SGN-35). Clin Cancer Res. 2011;17:6428–36.PubMedCrossRef
10.
Zurück zum Zitat Adcetris: EPAR, Product Information, October 2012. www.ema.europa.eu. Adcetris: EPAR, Product Information, October 2012. www.ema.europa.eu.
12.
Zurück zum Zitat Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Ann Rev Med. 2013;64:15–29.PubMedCrossRef Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Ann Rev Med. 2013;64:15–29.PubMedCrossRef
Metadaten
Titel
Durable complete remission after brentuximab vedotin in a patient with relapsed and refractory Hodgkin lymphoma (HL)
verfasst von
Prof. Dr. Johannes Drach, MD
Ihor Huk
Wolfgang Lamm
Publikationsdatum
01.06.2013
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2013
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-013-0078-8

Weitere Artikel der Ausgabe 2/2013

memo - Magazine of European Medical Oncology 2/2013 Zur Ausgabe